Adalta Ltd has released a press release.
European Patent for AD-214 granted
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from AdAlta
- BIO International Convention presentation
- AdAlta presentation at Bioshares Biotech Summit
- Indian patent for AD-214
- Inhaled AD-214 preclinical program
- PAC Partners Healthcare Conference - Corporate Presentation
Later from AdAlta
- AD-214 program update, cash runway extension
- Quarterly Appendix 4C and Activities Report
- R&D Tax Incentive Refund received
- 1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer
- Balance of R&D Tax Incentive Refund received
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta